% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • weightbayou weightbayou May 20, 2013 12:20 AM Flag

    DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

    Not yet recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts in Transformation; Untreated Adult Acute Myeloid Leukemia
    Interventions: Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401; Drug: poly ICLC; Drug: decitabine; Other: laboratory biomarker analysis

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Weight CDX 1401 is a celldex compund not Astex. This may eventually beneifit Celldex not Astex . Celldex is a very interesting stock by the way I have owned it for some time. The use of Decitabine in this combo wont benefit Astex because it will be generic by the time this gets approved.

    • Another great patent just issued to Astex.
      United States Patent 8,445,502
      Bearss , et al. May 21, 2013

      Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
      The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.

      Inventors: Bearss; David J. (Cedar Hills, UT), Joshi-Hangal; Rajashree (Pleasanton, CA), Liu; Xiao-Hui (Sandy, UT), Phiasivongsa; Pasit (Brentwood, CA), Redkar; Sanjeev G. (Hayward, CA), Vankayalapati; Hariprasad (Draper, UT)
      Applicant: Name City State Country Type
      Bearss; David J. Joshi-Hangal; Rajashree Liu; Xiao-Hui Phiasivongsa; Pasit Redkar; Sanjeev G. Vankayalapati; Hariprasad Cedar Hills Pleasanton Sandy Brentwood Hayward Draper UT CA UT CA CA UT US US US US US US

      Assignee: Astex Pharmaceuticals, Inc. (Dublin, CA)
      Appl. No.: 12/906,640
      Filed: October 18, 2010

      Current U.S. Class: 514/267
      Current International Class: A01N 43/54 (20060101); A61K 31/505 (20060101)
      Field of Search: 514/267

      References Cited [Referenced By]

      Foreign Patent Documents

      WO 2005/037825 Apr., 2005 WO

      Primary Examiner: Leeser; Erich A
      Attorney, Agent or Firm: Seed IP Law Group PLLC

      Parent Case Text


      What is claimed is:
      1. A method of treating small cell lung cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of an oral pharmaceutical formulation comprising a pharmaceutically acceptable excipient and a hydrochloride sale of MP470, wherein MP470 has the following structure: ##STR00007## , wherein the pharmaceutical formulation is delivered in combination with at least on

    • This phase I trial studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome or acute myeloid leukemia. DEC-205-NY-ESO-1 fusion protein, called CDX-1401, is a full length NY-ESO-1 protein sequence fused to a monocolonal antibody against DEC-205, a surface marker present on many immune stimulatory cells. This drug is given with another substance called PolyICLC, which acts to provoke any immune stimulatory cells which encounter the NY-ESO-1-DEC-205 fusion protein to produce an immune response signal against NY-ESO-1. Immune cells which have thus been primed to react against NY-ESO-1 may then attack myelodysplastic or leukemic cells which express NY-ESO-1 after exposure to the drug decitabine. The chemotherapy drug decitabine is thought to act in several different ways, first, it may directly kill cancer cells, secondly, the drug can cause cancer cells to re-express genes that are turned off by the cancer, including the gene for NY-ESO-1. Giving DEC-205/NY-ESO-1 fusion protein (CDX-1401) and polyICLC together with decitabine may allow the immune system to more effectively recognize cancer cells and kill them.

      Sentiment: Strong Buy

    • DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
      This study is not yet open for participant recruitment.
      Verified May 2013 by Roswell Park Cancer Institute
      Roswell Park Cancer Institute
      National Cancer Institute (NCI)
      Information provided by (Responsible Party):
      Roswell Park Cancer Identifier:
      First received: April 12, 2013
      Last updated: May 7, 2013
      Last verified: May 2013
      History of Changes